Regenxbio reports Q3 2026 results and confirms upcoming gene‑therapy data releases
Regenxbio announced its third‑quarter 2026 financials, showing revenue of $9.2 million and a net loss of $40.7 million. The company said topline results from its ATMOSPHERE and ASCENT wet‑AMD trials are expected in the fourth quarter of 2026, and that the BLA filing for its Duchenne therapy RGX‑202 remains on schedule for the first quarter of 2027 with a possible accelerated approval in the second half of 2027. Cash and marketable securities stood at $251.0 million at quarter‑end, giving the firm runway into late 2027.
Why it matters
The upcoming data from the wet‑AMD studies could drive market expectations for a first‑in‑class therapy, while the on‑track BLA timeline for RGX‑202 suggests a potential regulatory milestone in 2027. The cash balance indicates the company can fund operations and trial activities through at least Q4 2027 without additional financing.
Key facts
- 1Revenue for the quarter ended September 30, 2026 was $9.2 million, down from $29.7 million a year earlier. prnewswire.com
- 2Net loss for the quarter was $40.7 million. prnewswire.com
- 3Cash, cash equivalents and marketable securities totaled $251.0 million as of September 30, 2026. prnewswire.com
- 4Topline data from the ATMOSPHERE and ASCENT pivotal wet‑AMD trials are expected in Q4 2026. stocktitan.net
- 5RGX‑202 BLA submission is planned for Q1 2027, with a potential accelerated approval in H2 2027. stocktitan.net
- 6A pre‑BLA meeting with the FDA is anticipated in Q4 2026. sec.gov
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.